DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Fluzoparib
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Tamoxifen
Drug: Toremifene
Drug: Abemaciclib
Drug: LHRH agonist

First Posted Date: 2023-06-06

Last Posted Date: 2024-02-08

Lead Sponsor: Fudan University

Target Recruit Count: 766

Registration Number: NCT05891093

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 12 locations

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Phase 3

Not yet recruiting

Conditions: HR+/HER2-breast Cancer

Interventions: Drug: Standard endocrine therapy plus Apatinib

First Posted Date: 2023-06-05

Last Posted Date: 2023-06-05

Lead Sponsor: Fudan University

Target Recruit Count: 916

Registration Number: NCT05889871

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Phase 3

Recruiting

Conditions: HER2 Positive Early Breast Cancer

Interventions: Drug: Docetaxel
Drug: carboplatin
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Epirubicin
Drug: cyclophosphamide

First Posted Date: 2023-06-01

Last Posted Date: 2023-06-27

Lead Sponsor: Fudan University

Target Recruit Count: 1406

Registration Number: NCT05883852

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

Not Applicable

Not yet recruiting

Conditions: Colorectal Carcinoma
Liver Metastases

Interventions: Procedure: anatomical liver resection
Procedure: nonanatomical liver resection

First Posted Date: 2023-05-31

Last Posted Date: 2023-05-31

Lead Sponsor: Fudan University

Target Recruit Count: 176

Registration Number: NCT05881746

Locations: 🇨🇳
Zhongshan hospital, Shanghai, Shanghai, China

Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Not Applicable

Not yet recruiting

Conditions: Colorectal Cancer Liver Metastases

Interventions: Drug: Cetuximab

First Posted Date: 2023-05-24

Last Posted Date: 2023-05-24

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT05873972

Locations: 🇨🇳
Zhongshan hosptial, Fudan University, Shanghai, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Phase 4

Recruiting

Conditions: Early-stage Breast Cancer

Interventions: Drug: Huaier granule

First Posted Date: 2023-05-23

Last Posted Date: 2023-09-28

Lead Sponsor: Fudan University

Target Recruit Count: 379

Registration Number: NCT05871437

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer

Recruiting

Conditions: Cervical Cancer
Immune Checkpoint Inhibitor
Chemoradiotherapy

Interventions: Drug: Treatment Group

First Posted Date: 2023-05-18

Last Posted Date: 2023-05-18

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT05863260

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase 3

Recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

Interventions: Drug: epirubicin,cyclophosphamide,paclitaxel
Drug: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab

First Posted Date: 2023-05-17

Last Posted Date: 2024-03-22

Lead Sponsor: Fudan University

Target Recruit Count: 606

Registration Number: NCT05862064

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer Stage I

Interventions: Drug: Capecitabine，Pyrotinib

First Posted Date: 2023-05-16

Last Posted Date: 2024-03-22

Lead Sponsor: Fudan University

Target Recruit Count: 1008

Registration Number: NCT05861271

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Phase 4

Not yet recruiting

Conditions: Breast Cancer Stage IV

Interventions: Drug: Huaier Granule

First Posted Date: 2023-05-16

Last Posted Date: 2023-09-26

Lead Sponsor: Fudan University

Target Recruit Count: 384

Registration Number: NCT05860907

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
The Fourth Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China
🇨🇳
The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy